Log In
BCIQ
Print this Print this
 

CEP1430

  Manage Alerts
Collapse Summary General Information
Company Celprogen Inc.
DescriptionSynthetic inhibitor molecule against pancreatic cancer
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationPancreatic cancer
Indication DetailsPancreatic cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today